top of page

Vertex Pharmacueticals / Entrada Therapeutics

Approach: EEV oligonucleotides


Oct. 2021 S1 filed with SEC states "We plan to submit an IND to the FDA for an EEV-PMO candidate for the treatment of [myotonic dystrophy T1] in 2023"

Dec. 8, 2022 Press Release discussing Vertex's licensing of ENTR-701

bottom of page